2. What is “Precision” or “Personalized” Medicine? Medicines targeting patient segments that will have an optimal response to therapy Building disease understanding to identify the right pathways and targets Linking disease understanding and clinical outcomes Precision Medicine Segmented, not personalized (5-20%+ patient subgroups, not individuals)
3. Right Target Genetic validation; Rare phenotypes What are we trying to accomplish? Right Drug (or Combinations) Selective design and delivery; Combinations for complex diseases Right Patient Phenotyping and Genotyping
4.
5. Right Target Genetic validation; Rare phenotypes What are we trying to accomplish? Right Drug and Combinations Selective design and delivery; Combinations for complex diseases Right Patient Phenotyping and Genotyping
6.
7.
8. Right Target Genetic validation; Rare phenotypes What are we trying to accomplish? Right Drug (or Combinations) Selective design and delivery; Combinations for complex diseases Right Patient Phenotyping and Genotyping
9. Molecular Subtypes in Lung Cancer An Evolving Landscape of Medical Need Seg. 1 K-ras mut No targeted therapy Chemotherapy ineffective Seg. 4 LKB1 PI3K/mTor Seg. 2 EML4/Alk crizotinib Seg. 3 EGFR erlotinib Seg. 5 MYC No therapy c-Met amplification/ErbB amplification EGFR T790M GK mutation EGFR T790M GK mutation/c-Met amplification Resistance mechanisms
10.
11. Note: Patients in trial composed of 2 nd to 4 th line. 1 st line response to Standard of Care: ~50%, 2 nd line: ~10%, 3 rd line: 3-5% Clinical Outcome for NSCLC Patients After Crizotinib Treatment
12. Pre-Treatment (FLT-PET) After 4 weeks of Crizotinib 43-yr old Male Non-smoker with NSCLC ALK Fusion
